Mosedipimod
Grundinformationen
- CAS
221139-79-3- Standard-SMILES
CCCCCC=CCC=CCCCCCCCC(=O)OC(COC(C)=O)COC(=O)CCCCCCCCCCCCCCC- InChIKey
GAKUNXBDVGLOFS-UHFFFAOYSA-N- Summenformel
- C39H70O6
- Durchschnittliche Molmasse
- 635 g/mol
- Monoisotopische Masse
- 634,51723995
Überblick
Mosedipimod has been used in trials studying the supportive care and treatment of Chemotherapy-induced Neutropenia.
Namen und Bezeichner
- Bevorzugter Name
- Mosedipimod
- IUPAC
- (1-acetyloxy-3-hexadecanoyloxypropan-2-yl) octadeca-9,12-dienoate
- Englischer Name
- EC-18 221139-79-3
- Summenformel
- C39H70O6
- Molmasse
- 634.97
Namen und Synonyme
mosedipimodumRefChem:819537acetylated diacylglycerol PLAGPLAG, (+-)1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG)1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol, acetylated diglyceride1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol221139-79-388928BS57EEc-18MosedipimodGTPL9771
Weitere Namen anzeigen
Mosedipimod EC-18EC-18 221139-79-31-Palmitoyl-2-linoleoyl-3-acetylglycerol9,12-Octadecadienoic acid (9Z,12Z)-, 1-[(acetyloxy)methyl]-2-[(1-oxohexadecyl)oxy]ethyl ester
SCHEMBL6513431
Datenbank-Bezeichner
- CAS
221139-79-3- PubChem CID
- 53827958
- ChEMBL
CHEMBL157366
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 14,1
- Polarare Oberfläche (TPSA)
- 78,9 Ų
- H-Brücken-Donoren
- 0
- H-Brücken-Akzeptoren
- 6
- Frei drehbare Bindungen
- 36
- Schwere Atome
- 45
- Formalladung
- 0
- Komplexität
- 744
Physikochemische Eigenschaften
- Siedepunkt
- 650.6 · 650.6±35.0 °C(Predicted)
- Dichte
- 0.947 · 0.947±0.06 g/cm3(Predicted)
- Kosmetik-Inhaltsstoffe Funktionen
- HUMECTANTSKIN CONDITIONINGSKIN CONDITIONING - EMOLLIENT
Chemie und Industrie
Pharmakologische Informationen
Mechanism of Action
Mosedipimod is a proprietary compound originally derived from Sika deer antler. It accelerates endocytic trafficking of Pattern Recognition Receptors which allows for the swift removal of PAMPs/DAMPs. This drug has been shown to improve lung function and reduce inflammation and fibrosis in animal models. Currently, mosedipimod is being investigated against chemoradiation-induced oral mucositis and neutropenia, as well as against COVID-19.
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…